Current ICI regimens for advanced MM include monotherapy with anti‐programmed cell death protein‐1 (PD‐1) antibodies such as nivolumab or pembrolizumab, as well as combination therapy with nivolumab and ipilimumab. Here, PDCD1 is linked to Miyoshi myopathy.